Lonza GroupFRA:LO3 +2.83%81 EV-to-FCF is -202.84 as of Jul. 02, 2026. GuruFocus rates FRA:LO3 with a GF Score™ of 81/100 and a GF Value™ of €642.72 (Fairly Valued). The stock has 3 warning signs investors should review. Among 97 Medical Diagnostics & Research companies, Lonza Group ranks worse than 1030926.8% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Lonza Group's Enterprise Value is €46,842 Mil.
Lonza Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-231 Mil. Therefore, Lonza Group's EV-to-FCF for today is -202.84.
The historical rank and industry rank for Lonza Group's EV-to-FCF or its related term are showing as below:
FRA:LO3'
s EV-to-FCF Range Over the Past 10 Years
Min: -454.59 Med: 24.31 Max: 391.7
Current: -189.92
During the past 13 years, the highest EV-to-FCF of Lonza Group was 391.70. The lowest was -454.59. And the median was 24.31.
FRA:LO3's EV-to-FCF is ranked worse than 100% of 97
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.85
vs FRA:LO3: -189.92
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lonza Group's PE Ratio (TTM) for today is calculated as:
Lonza Group's share price for today is €610.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lonza Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-4.255.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Lonza Group EV-to-FCF Related Terms
Lonza Group EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Lonza Group's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Lonza Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lonza Group EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lonza Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Lonza Group's EV-to-FCF falls into.
Lonza Group's current Enterprise Value is €46,842 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lonza Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-231 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lonza Group (FRA:LO3) has a EV-to-FCF of -202.84 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Lonza Group and its competitors. According to the industry distribution chart, Lonza Group ranks #999999 out of 97 companies in the Medical Diagnostics & Research industry.
Is Lonza Group's EV-to-FCF too high?
Lonza Group's current EV-to-FCF is -202.84. Based on the distribution chart, Lonza Group ranks #999999 out of 97 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Lonza Group has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lonza Group's EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lonza Group ranks #999999 out of 97 companies for EV-to-FCF. This places Lonza Group in the lower half of its industry. The industry median EV-to-FCF is 22.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 22.85, based on 97 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Lonza Group and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 22.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lonza Group's current EV-to-FCF is -202.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lonza Group stock overvalued right now?
Based on GuruFocus' analysis, Lonza Group (FRA:LO3) is currently considered Fairly Valued. The stock's GF Value™ is €642.72, compared to a current price of €610.00 — trading 5.1% below its estimated fair value. The current EV-to-FCF is -202.84. Lonza Group's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Lonza Group (FRA:LO3), the current EV-to-FCF is -202.84 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lonza Group (FRA:LO3) Overvalued in 2026?
Based on GuruFocus' analysis, Lonza Group stock appears to be undervalued.
The current stock price of €610.00 is trading 5.1% below its estimated GF Value™ of €642.72.
GuruFocus considers Lonza Group to be Fairly Valued.
Key valuation signals for FRA:LO3:
EV-to-FCF: -202.84
GF Value™: €642.72 vs. price of €610.00 (5.1% below fair value)
No single metric tells the full story. See the FRA:LO3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
81GF Score
Get the complete analysis for FRA:LO3
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LO3 has been successfully added to your 
